Patients with locally advanced hepatocellular carcinoma (HCC) from the Asia Pacific region had comparable overall survival (OS) regardless of whether they were treated with selective internal radiation therapy (SIRT) or sorafenib. However, SIRT appeared to be more tolerable than sorafenib, according to results of the phase III SIRveNIB* trial.
The addition of low-dose cisplatin plus fluorouracil hepatic arterial infusion chemotherapy to sorafenib provides no additional survival benefit over sorafenib alone for patients with advanced, unresectable hepatocellular carcinoma, a recent randomized phase III study has shown.
Ablative chemoembolization (ACE) doubles response rate and progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC) compared with conventional transarterial chemoembolization (cTACE), a study by the Chinese University of Hong Kong (CUHK) has shown.
Infants delivered via caesarean section may be at increased risk of developing acute lymphoblastic leukaemia, according to a US study. Altered microbiota colonization is a possible explanation for this risk, although clear biological mechanisms have yet to be established.
Treatment with danegaptide does not improve myocardial salvage in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention, according to the results of a phase II study.